Drug Topics
FEBRUARY 27, 2025
As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.
STAT
FEBRUARY 26, 2025
The Food and Drug Administration canceled an upcoming vaccine advisory committee meeting to discuss influenza virus strains, according to committee member Paul Offit. The meeting was scheduled for March 13. Committee members received a cancellation email — which was first reported by Jeremy Faust of Inside Medicine — on Wednesday afternoon.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
FEBRUARY 24, 2025
Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.
European Pharmaceutical Review
FEBRUARY 26, 2025
A study has demonstrated a new approach to prepare tablets for intestinal drug delivery by combining two 3D printing techniques. Using both selective laser sintering (SLS) and fused deposition modelling (FDM), the technique has potential to achieve delayed and prolonged drug release, according to the findings. Key findings from the 3D printing drug delivery study [a] laser speed of 90 mm s1 was suitable for producing [3D printed tablet] cores with relatively short disintegration time and suffici
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
FEBRUARY 27, 2025
Researchers conducted a cross-sectional study to investigate the accessibility of over-the-counter naloxone and nonprescription syringes at community pharmacies.
STAT
FEBRUARY 25, 2025
After a top UnitedHealth Group executive was gunned down in New York City in December , the company’s risk intelligence team combed the internet for new threats. It didn’t take long to find them. The night of the shooting, a chilling entry appeared at the bottom of another executive’s LinkedIn post: “You’re next.” The following morning, Minnetonka police interviewed that executive at the company’s office in the otherwise sleepy, snow-covered Minne
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
PharmaVoice
FEBRUARY 27, 2025
Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.
Drug Topics
FEBRUARY 25, 2025
Miudella achieves similar efficacy to other available copper IUDs with less than half the dose of copper.
STAT
FEBRUARY 25, 2025
The tiny number of Indigenous students in U.S. medical schools has long been a concern, but Native American medical leaders were taken aback to see 22% fewer American Indian or Alaska Native students had enrolled last year when numbers were released in January. “It’s pathetic, isn’t it? It’s so small,” said Donald Warne, a Lakota physician and co-director of the Center for Indigenous Health at the Johns Hopkins Bloomberg School of Public Health, as he looked cl
The Checkup by Singlecare
FEBRUARY 25, 2025
Linzess (linaclotide) is a brand-name medication that has long been FDA approved to treat chronic constipation from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). In 2023, the FDA also approved Linzess as the first treatment for pediatric functional constipation, a condition in children and adolescents that causes infrequent bowel movements and hard stools that are difficult to pass.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmaVoice
FEBRUARY 28, 2025
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
Drug Topics
FEBRUARY 26, 2025
US Secretary of Agriculture Brooke Rollins detailed her organizations plans to combat the bird flu and quell the concerns of rising grocery store costs.
STAT
FEBRUARY 25, 2025
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at a list price of about $1,000 per month, but Lilly last year launched the lowest doses of the medication, 2.5 milligrams and 5 milligrams, in vials at $399 and $549 a month.
Fierce Healthcare
FEBRUARY 25, 2025
Republican holdouts, who stated repeatedly they would not vote for the bill, ultimately opted to advance legislation which will require significant Medicaid cuts.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
FEBRUARY 24, 2025
The FDAs accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
Drug Topics
FEBRUARY 25, 2025
The increased risk of symptoms only includes respiratory-related symptoms or brain fog.
STAT
FEBRUARY 27, 2025
Biotech venture capital is on the precipice of a generational shift. At least, that’s according to the crowd of younger firm founders edging their way in. There’s long been a small batch of scientists and business leaders who invest in drug companies. For the first 15 years of the 21st century, you’d find only 400, maybe 450 VC firms regularly giving money to drug startups — biotech’s own version of The Four Hundred , with lab coats or branded polar fleece, rat
pharmaphorum
FEBRUARY 25, 2025
Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PharmaVoice
FEBRUARY 25, 2025
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.
Drug Topics
FEBRUARY 28, 2025
With the disease burden remaining high, CVS Health announces new flu testing and treatment capabilities at approximately 1600 locations in selected states.
STAT
FEBRUARY 25, 2025
Since the end of World War II, the business plan of American universities has included two key principles that now are undergoing rapid disruptive change: Student-athletes participate in college sports in exchange for tuition, room, and board. Federal funding for academic research is the primary engine for the nation’s basic science enterprise.
Fierce Healthcare
FEBRUARY 28, 2025
The HHS secretary said the public feedback mechanism is an obligation that imposes burden on the department. Not all types of rulemaking are exempt, and it remains to be seen just how much of the department's activity does or does not legally require public comment.
PharmD Live
FEBRUARY 26, 2025
As specialty medications revolutionize treatment for chronic and complex conditions, their rising costs and intricate management requirements place a significant strain on patients, payers and providers. Without structured oversight, adherence issues, adverse drug interactions and financial barriers can lead to poor outcomes and unnecessary healthcare costs.
Drug Topics
FEBRUARY 28, 2025
Exploring data from the past 20 years, researchers investigated the end-organ complications from alcohol in adolescents and young adults.
STAT
FEBRUARY 27, 2025
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Health care investor Kevin Tang buys “zombie” biotechs to shut them down. It’s a counterintuitive, but ingenious solution to the sector’s intractable problem covered in last week’s newsletter.
European Pharmaceutical Review
FEBRUARY 25, 2025
Scientists have developed a new, potentially safer method to produce ethylene oxide. Based on the proposed technique, adding small amounts of nickel atoms to silver catalysts can maintain production efficiency while eliminating the need for chlorine, leading to a reduced environmental impact for ethylene oxide manufacturing. What sparked this development?
Fierce Healthcare
FEBRUARY 26, 2025
National telehealth giant Teladoc reported a massive loss in 2024, dragged down by the declining value of its BetterHelp direct-to-consumer mental health business. | Teladoc released its full-year 2024 earnings on Wednesday.
Drug Topics
FEBRUARY 28, 2025
Researchers compared hospitalization and mortality outcomes of older adults with and without restricted access to nirmatrelvir-ritonavir.
STAT
FEBRUARY 25, 2025
In recent years, an idea has taken hold across the ideological spectrum: The rise in diabetes and obesity in the United States is attributable to addictive, ultra-processed foods that dominate the American diet. But many people who are enthusiastically objecting to ultra-processed foods have little (if any) understanding of what the phrase means. Legislatures, governors, government agencies, and plaintiff attorneys are taking action against ultra-processed foods, but there is no clear defi
European Pharmaceutical Review
FEBRUARY 27, 2025
Researchers at Pohang University of Science and Technology (POSTECH), South Korea, have developed a super-photostable organic dye. The discovery sets a new benchmark for organic fluorophores, Professor Young-Tae Chang explained, providing potential applications in broad areas such as drug development and cellular imaging. Single-molecule imaging uses fluorescent markers to track proteins with precision.
Fierce Healthcare
FEBRUARY 24, 2025
Elon Musk is facing a lawsuit from federal workers over a mass email requiring government employees to list productive tasks from the prior week or risk termination. HHS leadership has instructed its staff not to respond to the message, at least temporarily.
Drug Topics
FEBRUARY 28, 2025
Chris Robinson, MD, PhD, joined Drug Topics to discuss the importance of education in newly explored technologies for the treatment of pain.
STAT
FEBRUARY 28, 2025
2025 bracket Welcome to STAT Madness, a bracket-style contest to find the best innovation in science and medicine. Explore groundbreaking innovations from top institutions and help crown the 2025 STAT Madness champion. Your vote determines who advances in this competition celebrating the best in biomedical research.
Expert insights. Personalized for you.
516 
Let's personalize your content